3-methyl-5-phenylthiophene-2-carboxylic acid | 23806-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 3-methyl-5-phenylthiophene-2-carboxylic acid
• 英文别名: 3-methyl-5-phenyl-2-thenoic acid；3-methyl-5-phenyl-thiophene-2-carboxylic acid；5-Phenyl-3-methyl-2-carboxy-thiophen
• CAS: 23806-25-9
• 化学式: C₁₂H₁₀O₂S
• 分子量: 218.276
• InChiKey: HKLGQHBZEAPLDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methyl-5-phenylthiophene-2-carboxylic acid 在 偶氮二异丁腈 N-溴代丁二酰亚胺(NBS) 、 铜 作用下， 以 喹啉 、 四氯化碳 为溶剂， 反应 3.0h， 生成 2-bromo-3-methyl-5-phenylthiophene
  参考文献：
  名称：

  Campaigne, E.; White, R.L., Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 367 - 373

  摘要：

  DOI：
• 作为产物：
  描述：

  4-methyl-2-phenylthiophene 在 偶氮二异丁腈 N-溴代丁二酰亚胺(NBS) 、 magnesium 作用下， 以 四氯化碳 为溶剂， 反应 4.0h， 生成 3-methyl-5-phenylthiophene-2-carboxylic acid
  参考文献：
  名称：

  Campaigne, E.; White, R.L., Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 367 - 373

  摘要：

  DOI：

文献信息

• Caspase inhibitors and uses thereof
  申请人：——

  公开号：US20030096737A1

  公开（公告）日：2003-05-22

  The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor- (IGIF), interferon-&ggr;- (“IFN-&ggr;”), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-&ggr; production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-&ggr;-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.

  本发明涉及一种新型的化合物类别，其化学式为I，可作为caspase和TNF-alpha的抑制剂。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制caspase和TNF-alpha的活性，因此可以作为对抗caspase、白细胞介素-1（“IL-1”）、凋亡、干扰素-γ诱导因子（IGIF）、干扰素-γ（“IFN-γ”）或TNF-alpha介导的疾病的药物，包括炎症性疾病、自身免疫性疾病、破坏性骨疾病、增生性疾病、感染性疾病和退行性疾病。本发明还涉及制备这些化合物的方法。本发明还涉及使用这些化合物和组合物来抑制caspase和TNF-alpha的活性，降低IGIF和IFN-γ的产生以及治疗caspase、白细胞介素-1、凋亡和干扰素-γ和TNF-alpha介导的疾病的方法。
• AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：BIAN Haiyan

  公开号：US20100324012A1

  公开（公告）日：2010-12-23

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Y, Z, R 1 , and s are defined herein.

  本发明涉及化合物、组合物和方法，用于治疗各种疾病、综合症、状况和障碍，包括疼痛。这些化合物由下式（I）所表示：其中Y、Z、R1和s在此定义。
• Synthesis and Pharmacological Characterization of N³-Substituted Willardiine Derivatives:  Role of the Substituent at the 5-Position of the Uracil Ring in the Development of Highly Potent and Selective GLU_K5 Kainate Receptor Antagonists
  作者：Nigel P. Dolman、Julia C. A. More、Andrew Alt、Jody L. Knauss、Olli T. Pentikäinen、Carla R. Glasser、David Bleakman、Mark L. Mayer、Graham L. Collingridge、David E. Jane

  DOI：10.1021/jm061041u

  日期：2007.4.1

  Some N-3-substituted analogues of willardiine such as 11 and 13 are selective kainate receptor antagonists. In an attempt to improve the potency and selectivity for kainate receptors, a range of analogues of 11 and 13 were synthesized with 5-substituents on the uracil ring. An X-ray crystal structure of the 5-methyl analogue of 13 bound to GLU(K5) revealed that there was allowed volume around the 4- and 5-positions of the thiophene ring, and therefore the 4,5-dibromo and 5-phenyl (67) analogues were synthesized. Compound 67 (ACET) demonstrated low nanomolar antagonist potency on native and recombinant GLU(K5)-containing kainate receptors (K-B values of 7 +/- 1 and 5 +/- 1 nM for antagonism of recombinant human GLU(K5) and GLU(K5)/GLU(K2), respectively) but displayed IC50 values > 100 mu M for antagonism of GLU(A2), GLU(K6), or GLU(K6)/GLU(K2).
• CAMPAIGNE, E.;WHITE, R. L. (JR), J. HETEROCYCL. CHEM., 25,(1988) N 2, 367-373
  作者：CAMPAIGNE, E.、WHITE, R. L. (JR)

  DOI：——

  日期：——
• HETEROCYCLYLDICARBAMIDES AS CASPASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1381602A1

  公开（公告）日：2004-01-21